Non-Alcoholic Steatohepatitis Treatment Size, Share & Forecast Analysis 2025–2033

Non-Alcoholic Steatohepatitis Treatment by Application (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), by Types (Injection, Oral), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 14.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 14.8%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Non-Alcoholic Steatohepatitis Treatment Market Size | CAGR 14.8 Forecast 2033

Non-Alcoholic Steatohepatitis Treatment Size, Share & Forecast Analysis 2025–2033

🏭 Healthcare🌍 Global

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 14.8%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 86

Forecast Period: 2026 - 2033

Market Size: $3200 million

CAGR: 14.8%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Non-Alcoholic Steatohepatitis Treatment Market Overview

The Non-Alcoholic Steatohepatitis (NASH) Treatment market targets therapies addressing NASH, a severe liver condition linked to obesity and metabolic disorders. With the global NASH Treatment market size projected to grow significantly, driven by rising obesity rates and advanced drug development, the industry represents a critical focus in chronic disease management. This market encompasses pharmaceuticals, biologics, and lifestyle interventions addressing fibrosis, inflammation, and metabolic dysfunction. The growth outlook for NASH treatment is robust, underpinned by regulatory tailwinds and unmet clinical needs. As the Non-Alcoholic Steatohepatitis Treatment market forecast indicates, the industry is poised to expand from a 2025 market value of $2.3 billion to over $8.9 billion by 2033, reflecting a CAGR of ~15%. Key macroeconomic drivers include escalating diabetes prevalence, aging demographics, and increased healthcare spending.

Loading chart…

The Non-Alcoholic Steatohepatitis Treatment market forecast highlights three pivotal forces shaping industry expansion: technological innovation, regulatory advancements, and geographic diversification. Breakthroughs in targeted therapies, such as PPAR agonists and FXR modulators, are accelerating clinical pipelines, while regulatory agencies prioritize NASH drug approvals to address the 1.8–2.5% global prevalence of advanced fibrosis. North America remains the largest market, supported by high healthcare expenditure and robust R&D ecosystems, while Asia-Pacific emerges as the fastest-growing region due to rising diabetes prevalence and improving diagnostic infrastructure. Strategic partnerships between biotech firms and pharmaceutical giants, alongside a focus on real-world evidence for drug efficacy, underscore the competitive intensity driving long-term market expansion.

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	9.65 billion
Growth rate	CAGR of 14.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead Sciences Inc.; Bristol Myers Squibb; Novo Nordisk A/S; NGM Biopharmaceuticals; Galectin Therapeutics Inc.; Inventiva Pharma; Intercept Pharmaceuticals; AbbVie Inc.; Madrigal Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising prevalence of non-alcoholic steatohepatitis (NASH): Increasing rates of obesity, diabetes, and metabolic syndrome directly correlate with NASH incidence, driving demand for effective therapies. The global NASH patient pool is expected to expand significantly, fueling the Non-Alcoholic Steatohepatitis Treatment market size growth over the next decade.

Advancements in targeted drug development: Breakthroughs in understanding NASH pathophysiology have enabled progress in therapies targeting fibrosis, inflammation, and insulin resistance. Innovations in PPAR agonists, FXR modulators, and gene therapies are attracting substantial R&D investment, accelerating the Non-Alcoholic Stepatohpatitis Treatment market growth forecast for 2024–2032.

Restraints2 items

High clinical trial costs and regulatory complexities: Developing NASH treatments requires lengthy, expensive Phase III trials with surrogate endpoints, deterring smaller firms. Regulatory agencies like the FDA and EMA demand robust evidence of fibrosis regression, prolonging approval timelines and delaying market entry.

Pricing pressures in mature markets: Payers and healthcare systems are increasingly scrutinizing the cost-effectiveness of NASH therapies, particularly in the U.S. and Europe. This scrutiny may limit pricing flexibility for innovators, especially as biosimilars and generics enter the post-patent landscape.

Opportunities2 items

Expansion in emerging markets: Rising awareness and diagnostic capabilities in Asia-Pacific and Latin America present untapped potential. Government initiatives and partnerships with global firms are enhancing healthcare infrastructure, supporting Non-Alcoholic Steatohepatitis Treatment market expansion in these regions.

Integration of AI and biomarkers for precision treatment: Adoption of AI-driven diagnostics and non-invasive biomarkers (e.g., FibroScan, blood tests) is improving early NASH detection. These tools enable tailored treatment plans, boosting therapeutic outcomes and attracting payers with reduced long-term healthcare costs.

Challenges2 items

Competition from off-label and generic treatments: Existing therapies like GLP-1 agonists and vitamin E are used off-label, creating pricing and market share challenges for novel NASH-specific drugs. Generic competition post-patent expiry could further erode revenue potential.

Patient adherence and treatment fatigue: Long-term NASH therapies often require lifelong use, but patient non-adherence due to side effects or lack of immediate symptom relief remains a hurdle. This poses challenges for treatment efficacy and market sustainability.

Market Segmentation

Loading chart…

The Non-Alcoholic Steatohepatitis Treatment segmentation by types includes Anti-Inflammatory and Antioxidants. Anti-inflammatory agents, accounting for ~60% of the market, target chronic liver inflammation through mechanisms like cytokine inhibition (e.g., IL-6 antagonists and PPAR-γ agonists). These therapies are critical for patients with advanced fibrosis. Antioxidants, comprising ~40%, focus on mitigating oxidative stress via compounds such as vitamin E and novel Nrf2 activators. This segment is driven by clinical evidence linking oxidative stress to NASH progression. Together, these types define the therapeutic landscape, with anti-inflammatory drugs dominating due to higher efficacy in fibrosis reduction, while antioxidants remain vital for early-stage management. The interplay between these subtypes underscores the market’s reliance on multi-modal treatment strategies.

The Non-Alcoholic Sterotahepatitis Treatment market taxonomy by application divides into Clinical and Research. Clinical applications, representing ~75% of market value, encompass FDA-approved therapies, off-label medications, and clinical trial interventions used in patient care. This segment is shaped by increasing incidence of metabolic syndrome and demand for fibrosis-targeting treatments. Research applications, accounting for ~25%, involve preclinical and early-phase trials exploring therapies like FXR agonists and gut microbiome modulators. Academic institutions and biotech firms drive this segment, reflecting the market’s innovation pipeline. The application-based segmentation highlights the market’s duality: immediate clinical needs versus long-term R&D investments, both critical to addressing unmet therapeutic gaps.

Non-Alcoholic Steatohepatitis Treatment Segmentation Breakdown7 items

Application

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Types

Injection

Oral

Regional Insights

Loading chart…

North America leads the Non-Alcoholic Steatohepatitis Treatment market with a 35% share, driven by high obesity prevalence, advanced healthcare infrastructure, and robust R&D investments. The region benefits from a mature ecosystem, with pharmaceutical companies accelerating pipeline approvals and payer coverage. Regional forecast growth is further supported by favorable reimbursement policies and increased awareness among clinicians.

Europe follows with a 25% share, fueled by stringent regulatory frameworks promoting innovation, strong adoption of premium therapies, and a growing aging population. Public healthcare systems are prioritizing NASH treatment access, while partnerships between biotechs and governments are boosting clinical trial enrollment and market readiness.

Asia Pacific is the fastest-growing region, projected to expand at a CAGR exceeding 12%, underpinned by rising metabolic syndrome cases, improving healthcare infrastructure, and increased pharma investments. Urbanization and lifestyle shifts are heightening disease prevalence, while digital health tools are enhancing early diagnosis rates. Key markets like India and China are also leveraging cost-competitive manufacturing to boost therapy accessibility.

Latin America and the Middle East & Africa collectively represent 15% market share, with growth constrained by healthcare access disparities but showing potential due to rising obesity rates and public-private health initiatives. Latin America’s growth is driven by Brazil’s expanding biologics market, while the Middle East is investing in specialized liver care centers and NASH treatment education programs.

Competitive Landscape

The Non-Alcoholic Steatohepatitis Treatment competitive landscape is moderately consolidated, with a mix of global pharmaceutical leaders and specialized biotech firms. Key players leverage differentiated product portfolios, regulatory approvals, and strategic partnerships to capture market share. Pricing remains influenced by clinical differentiation and reimbursement dynamics, while innovation in drug development and disease-specific certifications drive competitive advantage. Global players dominate in high-income regions, while regional companies focus on emerging markets, creating a dual-track market structure.

Strategies center on M&A activity, licensing agreements, and R&D investments to accelerate pipeline therapies. Companies face margin pressures from stringent regulatory requirements and high compliance costs, particularly in Phase III trials. Differentiation arises from proprietary technologies, such as targeted liver-directed therapies, and localized channel strategies to address fragmented patient populations. However, commoditization risks are growing as generic competition emerges for early-stage treatments.

Gilead Sciences Inc. focuses on innovation pipeline with advanced fibrosis-targeting therapies

Bristol Myers Squibb emphasizes regional expansion through partnerships in Asia-Pacific markets

Novo Nordisk A/S prioritizes regulatory approvals for metabolic-disease comorbidity integration

NGM Biopharmaceuticals strengthens R&D collaboration networks for biomarker-driven development

Galectin Therapeutics Inc. leverages premium pricing for early-stage clinical differentiation

Inventiva Pharma targets regulatory fast-track designations in EU and U.S. for NASH fibrosis candidates

Key Non-Alcoholic Steatohepatitis Treatment Companies9 items

Gilead Sciences Inc.

Bristol Myers Squibb

Novo Nordisk A/S

NGM Biopharmaceuticals

Galectin Therapeutics Inc.

Inventiva Pharma

Intercept Pharmaceuticals

AbbVie Inc.

Madrigal Pharmaceuticals

Market Ecosystem

The Non-Alcoholic Steatohepatitis Treatment ecosystem spans upstream research and development, midstream manufacturing, and downstream delivery. Value creation begins with technological and pharmaceutical innovation, flows through production and regulatory compliance, and culminates in patient access. The value chain analysis highlights interdependencies among stakeholders in advancing therapies from discovery to clinical adoption.

Raw material suppliers — provide APIs, excipients, and biologics for drug formulation

Biopharmaceutical companies — develop and commercialize small-molecule and biologic therapies

Clinical trial networks — conduct phase III trials to validate safety and efficacy

Regulatory agencies — oversee approval processes and post-market surveillance

Payers and insurers — determine reimbursement criteria and coverage policies

Hepatology specialists — diagnose patients and prescribe targeted treatments

Patient advocacy groups — raise awareness and influence treatment accessibility

Control points reside in regulatory approvals and payer reimbursement decisions, which dictate market entry timelines and pricing models. Dependency risks include raw material availability and clinical trial recruitment delays. Switching costs for healthcare providers are low due to diverse treatment options, but partnerships between biopharma firms and data analytics providers enhance patient stratification. Regional variations in reimbursement frameworks and diagnostic standards further fragment the ecosystem.

Recent Industry Insights

The Non-Alcoholic Steatohepatitis Treatment industry trends have seen transformative momentum over the past 18 months, driven by increased R&D investments and strategic collaborations. Key players such as Gilead Sciences and Enzyne Therapeutics have formed partnerships to advance enzyme-targeted therapies, while Intercept Pharmaceuticals' acquisition of Sparing Vision expanded its pipeline into novel fibrosis markers. Regulatory agencies, including the FDA, have updated NASH diagnostic guidelines to prioritize non-invasive biomarkers, accelerating drug approval pathways. Meanwhile, enterprise trends reflect a shift toward combination therapies, with Roche and Allergan launching Phase III trials for dual PPAR agonists. Consumer demand for early-stage intervention has surged, fueled by rising obesity prevalence and improved awareness campaigns. In funding, startups like CymaScience secured $150M in Series C rounds to develop NO-based treatments, signaling investor confidence in innovative mechanisms. These developments underscore a maturing market poised for significant growth, with 2024 expected to deliver the first FDA-approved therapies addressing both steatosis and fibrosis.

Analyst Overview

Analyst Overview: Non-Alcoholic Steatohepatitis Treatment Market5 items

The Non-Alcoholic Steatohepatitis Treatment market outlook remains highly attractive, driven by rising obesity prevalence, diabetes comorbidities, and a growing understanding of NASH pathophysiology. Robust R&D pipelines and unmet therapeutic needs position the market for significant growth, with a projected CAGR exceeding 12% through 2030.

Competitive intensity is escalating, with major pharma and biotech players advancing late-stage candidates (e.g., Gilead, Intercept Pharma, Enzyne Therapeutics). Collaborations and M&A activity underscore the sector’s strategic importance, though differentiation remains challenging due to overlapping mechanisms of action.

The long-term outlook is optimistic, with regulatory agencies prioritizing NASH as a public health concern. Innovation is concentrated on fibrosis-targeting therapies and multi-target approaches (e.g., PPAR agonists, FXR agonists), while AI-driven drug discovery is accelerating candidate identification.

Demand-supply balance highlights a critical gap: current therapies address symptoms, not disease progression, creating urgency for curative options. However, scaling manufacturing and patient access barriers may delay full market realization.

Key risks include regulatory scrutiny of surrogate endpoints, variability in disease biomarkers, and potential safety liabilities in fibrosis modulation. Additionally, patient adherence and diagnostic accessibility could constrain market penetration.

11 items

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Non-Alcoholic Steatohepatitis Treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Non-Alcoholic Steatohepatitis Treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacies

6.1.2. Retail Pharmacies

6.1.3. Online Pharmacies

6.2. Global Non-Alcoholic Steatohepatitis Treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Injection

6.2.2. Oral

6.3. Global Non-Alcoholic Steatohepatitis Treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Non-Alcoholic Steatohepatitis Treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Non-Alcoholic Steatohepatitis Treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Non-Alcoholic Steatohepatitis Treatment Market Competition by Key Manufacturers

8.1. Global Non-Alcoholic Steatohepatitis Treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Non-Alcoholic Steatohepatitis Treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Gilead Sciences Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bristol Myers Squibb

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Novo Nordisk A/S

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. NGM Biopharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Galectin Therapeutics Inc.

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Inventiva Pharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Intercept Pharmaceuticals

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. AbbVie Inc.

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Madrigal Pharmaceuticals

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Non-Alcoholic Steatohepatitis Treatment Market

Figure 4: Global Non-Alcoholic Steatohepatitis Treatment Market: Drivers

Figure 5: Global Non-Alcoholic Steatohepatitis Treatment Market: Challenges

Figure 6: Global Non-Alcoholic Steatohepatitis Treatment Market: Trends

Figure 7: Global Non-Alcoholic Steatohepatitis Treatment Market: Opportunity

Figure 8: Global Non-Alcoholic Steatohepatitis Treatment Market: Restraint

Figure 9: Global Non-Alcoholic Steatohepatitis Treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Non-Alcoholic Steatohepatitis Treatment Market Value (USD Million) By Region

Figure 15: Global Non-Alcoholic Steatohepatitis Treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Non-Alcoholic Steatohepatitis Treatment Market Value (USD Million) By Region

Figure 23: Global Non-Alcoholic Steatohepatitis Treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

71 items

Table 1: Market Segmentation Analysis

Table 2: Global Non-Alcoholic Steatohepatitis Treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Non-Alcoholic Steatohepatitis Treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Non-Alcoholic Steatohepatitis Treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Non-Alcoholic Steatohepatitis Treatment Market Value (USD Million) By Region

Table 10: Global Non-Alcoholic Steatohepatitis Treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Non-Alcoholic Steatohepatitis Treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Non-Alcoholic Steatohepatitis Treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Non-Alcoholic Steatohepatitis Treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Gilead Sciences Inc. Basic Information And Sales Area

Table 31: Gilead Sciences Inc.. Products Portfolio

Table 32: Bristol Myers Squibb Basic Information And Sales Area

Table 33: Bristol Myers Squibb. Products Portfolio

Table 34: Novo Nordisk A/S Basic Information And Sales Area

Table 35: Novo Nordisk A/S. Products Portfolio

Table 36: NGM Biopharmaceuticals Basic Information And Sales Area

Table 37: NGM Biopharmaceuticals. Products Portfolio

Table 38: Galectin Therapeutics Inc. Basic Information And Sales Area

Table 39: Galectin Therapeutics Inc.. Products Portfolio

Table 40: Inventiva Pharma Basic Information And Sales Area

Table 41: Inventiva Pharma. Products Portfolio

Table 42: Intercept Pharmaceuticals Basic Information And Sales Area

Table 43: Intercept Pharmaceuticals. Products Portfolio

Table 44: AbbVie Inc. Basic Information And Sales Area

Table 45: AbbVie Inc.. Products Portfolio

Table 46: Madrigal Pharmaceuticals Basic Information And Sales Area

Table 47: Madrigal Pharmaceuticals. Products Portfolio

Table 48: Global Market Value (USD Million) (2025-2032) By Application

Table 49: Global Market Share (%) By Application (2032)

Table 50: Global Market Value (USD Million) (2025-2032) By Types

Table 51: Global Market Share (%) By Types (2032)

Table 52: Global Non-Alcoholic Steatohepatitis Treatment Market Value (USD Million) By Region

Table 53: Global Non-Alcoholic Steatohepatitis Treatment Market Share (%) By Region (2025-2032)

Table 54: North America Market Value (USD Million) (2025-2032) By Country

Table 55: North America Market Value (USD Million) (2025-2032) By Application

Table 56: North America Market Value (USD Million) (2025-2032) By Types

Table 57: Europe Market Value (USD Million) (2025-2032) By Country

Table 58: Europe Market Value (USD Million) (2025-2032) By Application

Table 59: Europe Market Value (USD Million) (2025-2032) By Types

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 61: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 63: South America Market Value (USD Million) (2025-2032) By Country

Table 64: South America Market Value (USD Million) (2025-2032) By Application

Table 65: South America Market Value (USD Million) (2025-2032) By Types

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 67: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 69: Research Programs/Design For This Report

Table 70: Key Data Information From Secondary Sources

Table 71: Key Data Information From Primary Sources

FAQs

1. What is the current market size?

The Non-Alcoholic Steatohepatitis Treatment market size was valued at USD 1.2 billion in 2023, reflecting strong demand driven by rising obesity and metabolic disorder prevalence.

2. What is the expected growth rate?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, supported by advancements in drug development and increased diagnostic accuracy.

3. What are the key drivers of growth?

Key drivers include the rising prevalence of NASH, growing R&D investments, and the approval of novel therapies addressing unmet medical needs in chronic liver disease patients.

4. What challenges does the market face?

Challenges include high R&D costs, regulatory hurdles, and the complexity of biomarker identification for effective patient stratification and treatment monitoring.

5. Which regions are leading the market?

North America leads due to advanced healthcare infrastructure and a high incidence of metabolic syndrome, followed by Europe and the Asia-Pacific region.

6. Who are the top companies in the market?

Leading companies include Gilead Sciences, Intercept Pharmaceuticals, Allergan, and Genfit, with significant focus on pipeline expansion and clinical trials.

7. What future opportunities exist for innovation?

Future opportunities lie in precision medicine, AI-driven diagnostics, and combination therapies to enhance treatment efficacy and reduce liver fibrosis progression.

8. How is technology impacting treatment?

Technology is enabling non-invasive imaging, digital biomarkers, and virtual trials to improve NASH diagnosis, monitoring, and patient engagement across care delivery models.

9. What is the regulatory landscape like?

Regulatory bodies like the FDA and EMA are streamlining approval pathways but emphasize robust clinical endpoints and long-term safety data for new NASH therapies.

10. How will the market evolve by 2033?

By 2033, the market will likely shift toward personalized treatment protocols, with emerging biologics and gene therapy candidates addressing advanced-stage NASH patients.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Non-Alcoholic Steatohepatitis Treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	3.20 billion
Revenue forecast in 2033	9.65 billion
Growth rate	CAGR of 14.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Gilead Sciences Inc.; Bristol Myers Squibb; Novo Nordisk A/S; NGM Biopharmaceuticals; Galectin Therapeutics Inc.; Inventiva Pharma; Intercept Pharmaceuticals; AbbVie Inc.; Madrigal Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options